African Journal of
Pharmacy and Pharmacology

  • Abbreviation: Afr. J. Pharm. Pharmacol.
  • Language: English
  • ISSN: 1996-0816
  • DOI: 10.5897/AJPP
  • Start Year: 2007
  • Published Articles: 2239

Full Length Research Paper

Combination of lauric acid and myristic acid prevents benign prostatic hyperplasia (BPH) symptoms in animal model

Anup A. Patil*
  • Anup A. Patil*
  • Department of Pharmacology, Gourishankar College of Pharmacy, Limb,Satara, India.
  • Google Scholar
Veeresh, B.
  • Veeresh, B.
  • G Pulla Reddy College of Pharmacy, Hydrabad, India.
  • Google Scholar
Adikrao Yadav
  • Adikrao Yadav
  • Department of Pharmacology, Gourishankar College of Pharmacy, Limb,Satara, India.
  • Google Scholar


  •  Received: 15 December 2012
  •  Accepted: 20 January 2016
  •  Published: 29 February 2016

References

Arruzabala ML, Molina V, Mas R, Carbajal D, Marrero D, Gonzalez V, Rodriguez E (2006). Effect of coconut oil on tesetosterone induced prostastic hyperplasia in SD rats. J. Pharm. Pharmcol. 59(7):995-999.
crossref

 

Babu SV, Veeresh B, Patil AA, Warke YB (2010). Lauric acid and myristic acids prevents testosterone induced prostatic hyperplasia in rats. Eur. J. Pharmcol. 626(2):262-265.
crossref

 

Bartsch G, Rittmaster RS, Klocker H (2000). Dihydrotestosterone and 5- alpha reductase inhibition in human benign prostatic hyperplasia. Eur. Urol. 37(4):367-368.
crossref

 

Bisson JF, Hidalgo S, Rozan P, Messaoudi M (2007). Therapeutic effect of ACTICOA powder, a cocoa polyphenolic extract on experimentally induced prostate hyperplasia in Wistar-Unilever rats. J. Med. Food 10(4):628-635.
crossref

 

Carson C, Rittmaster R (2003). The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61(4):2-7.
crossref

 

Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T, Lzumi T, Abiko Y (1982). Alphaadrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J. Urol. 128(4):836-839.

 

Gasco M, Villegas L, Yucra S, Rubio J, Gonzales CF (2007). Dose-response effect of Red Maca (Lepidium myenii) on benign prostatic hyperplasia induced by testosterone enanthate. Phytomedicine 14(7):460-464.
crossref

 

Girman CJ, Jacobsen SJ, Guess HA, Oesterling JE, Chute CG, Panser LA, Lieber MM (1995). Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J. Urol. 153(5):1510-1515.
crossref

 

Griffiths K, Denis LJ (2000). Exploitable mechanisms for the blockade of androgenic action. Prostate 10(S10):43-51.
crossref

 

Jang H, Ha US, Kim SJ, Yoon BI, Han DS, Yuk SM, Kim SW (2010). Anthocyanin extracted from black soybean reduces prostate weight and promotes apoptosis in the prostatic hyperplasia-induced rat model. J. Agric. Food Chem. 58(24):12686-12691.
crossref

 

Lepor H (2000). The pathophysiology of lower urinary tract symptoms in the aging male population. In: Lepor H, editor. Prostatic diseases. Philadelphia, PA:WB Saunders. pp. 163-196.

 

Liang T, Liao S (1992). Inhibition of steroid 5 α-reductase by specific alpha1-adernoceptors subtype in humans car aliphatic unsaturated fatty acids. Biochem. J. 285:557-562.
crossref

 

McNeal JG (1983). The prostate gland: morphology and pathobiology. Monogr. Urol. 4:3-33.

 

Michel MC, Taguchi K, Schfers RS, Williams TJ, Clarke D, E, Ford AP (1998). alpha1-adernoceptors subtype in humans cardiovascular and urogenital system. Adv. Pharmcol. 42:394-398.
crossref

 

Niu YJ, Ma TX, Zhang J, Xu Y, Han RF, Sun G (2003). Androgen and prostatic stroma. Asian J. Androl. 5:19-26.

 

Pais P (2010). Potency of a novel saw palmetto extract, SPET-85, for inhibition of 5alpha-reductase II. Adv. Ther. 27:555-563.
crossref

 

Patel AK, Chapple CR (2008). Benign prostatic hyperplasia: Treatment in primary health care. BMJ 333:535-539.
crossref

 

Roehrborn CG (2011). Male lower urinary tract symptoms (LUTS) and benignprostatic hyperplasia (BPH). Med. Clin. North Am. 95(1):87-100.
crossref

 

Span PN, Völler MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, Kirby RS (1999). Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J. Urol. 161(1):332-337.
crossref